The Role of Platelet TLRs in Platelet Activation During VTE

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-10-11

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Venous thromboembolic disease (VTE) is a frequent and potentially serious pathology. Therapeutic management has improved considerably over the last few decades, enabling the application of codified management in line with the recently updated French management recommendations.

One of the main remaining difficulties concerns VTE sequelae, mainly post-thrombotic syndrome after deep vein thrombosis, and post-pulmonary embolism syndrome after pulmonary embolism. The mechanisms leading to the absence of complete repermeabilization of vessels affected by Venous thromboembolic disease (VTE) are still poorly understood.

The concept of immunothrombosis, closely associating immunity, inflammation and thrombosis, could (in part) explain the appearance of these sequelae. Platelets appear to play a key role in the onset of sequelae: Platelets are known to be involved both in the onset of a VTE episode and in the inflammatory response. This involvement is illustrated by the expression of inflammatory receptors such as TLR (toll-like receptor) 2 and TLR4.

Th aim to investigate the role of platelets in the occurrence of sequelae, mainly via their role in the inflammatory response, in Venous thromboembolic disease (VTE) patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Immature Plateletes in the Etiopathology of Deep Venous Thrombosis

NCT02361294

Immature Platelets Deep Venous Thrombosis

COMPLETED

Best Antithrombotic Therapy in Patients With Acute Venous ThromboEmbolism While Taking Antiplatelets

NCT05627375

Venous Thromboembolic Disease

RECRUITING PHASE3

Incidence of Venous Thromboembolism and Professional Practices in Brest Area

NCT02895971

Venous Thromboembolism

COMPLETED

A Clinical Cohort Study of Safety and Effectiveness of Venous Thromboembolism Prophylaxis in Critical Ill Patients

NCT02213978

Venous Thromboembolism Hemorrhage

COMPLETED

Cohort for Monitoring Patients With Venous Thromboembolic Disease

NCT07016542

Venous Thromboembolic Disease

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Venous Thromboembolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Venous ThromboEmbolic (VTE) patients

a diagnosis of Venous ThromboEmbolic (VTE) less than 72 hours old at inclusion, with a follow-up of 3 to 6 months

blood sample

Intervention Type BIOLOGICAL

at Day 1 - date of patient inclusion at time of VTE diagnosis

blood sample

Intervention Type BIOLOGICAL

at 6 months (in the patient follow-up)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

blood sample

at Day 1 - date of patient inclusion at time of VTE diagnosis

Intervention Type BIOLOGICAL

blood sample

at 6 months (in the patient follow-up)

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with Venous ThromboEmbolic (VTE) / Proximal Deep vein thrombosis (DVT) of the lower limb and/or pulmonary embolism ≤ 72heures
* Patients are 18 years of age or older at diagnosis.
* Patients received informed written consent
* Patients benefiting from social security coverage

Exclusion Criteria

* Diagnosis of Venous ThromboEmbolic (VTE) more than 72 hours old
* Isolated sub-segmental pulmonary embolism
* Patients on antiplatelet agents
* Patients on non-steroidal anti-inflammatory drugs (NSAIDs)
* Life expectancy \> 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No